Content media

Bionano Genomics Announces Extensive Range of Content to

  • Dr Alka Chaubey, Chief Medical Officer at Bionano, Dr Nikhil Sahajpal, Greenwood Genetic Center, Dr. Rashmi Kanagal-Shamanna, MD Anderson and Dr. Adam Smith Cancer Center, The University Health Network will host a sponsored supplier presentation on studies that include multiple types of hematological malignancies and highlight the benefits of combining optical genome mapping (OGM) with next-generation sequencing (NGS) to maximize actionable outcomes
  • A scientific presentation with Dr. Chaubey, Dr. Kanagal-Shamanna, Dr. Ravindra Kolhe, Augusta University, and Dr. Christopher Lum, Queens Medical Center wsick cover methodologies for homologous recombination deficiency (HRD), including NGS, microarray and GMO, as well as bioinformatics approaches for the analysis of solid tumor and hematological malignancies data
  • A plenary session will feature Dr. Smith giving a presentation on the implementation of long-read sequencing (LRS) and GMO for cytogenetic research, and will be immediately followed by a panel discussion on the use of new tools, including GMO, in the next generation cytogenomics, with Dr. Smith, Dr. Eric Duncavage, Washington University School of Medicine, Dr. Yassmine Akkari, National Children’s Hospital and Dr. Robert Hasserjian, Massachusetts General Hospital
  • Eleven scientific posters presenting the results of GMO applications in prenatal and postnatal analysis, research on solid tumors and hematological malignancies will be presented at the conference

SAN DIEGO, Oct. 28, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the 2022 Association for Molecular Pathology (AMP) Annual Meeting and Expo. with a wide range of content covering optics the usefulness of genome mapping (GMO) for research applications including prenatal and postnatal analysis, genetic diseases and hematological malignancies.

The AMP annual meeting brings together professionals from industry, medicine and academia to discuss advances in the field of molecular diagnostics. The AMP Conference will be held November 1-5, 2022 in Phoenix, Arizona.

Scientific presentations and poster sessions by Bionano and collaborators include:

Session Title Presenter Present
Corporate workshop Maximizing the detection of pathogenic structural variants in hematological malignancies using optical genome mapping Chaubey A., Sahajpal N., Kanagal-Shamanna R., Smith A. November 2, 2022
9:00 a.m. to 9:50 a.m. PDT
Room 229 AB
Corporate workshop Comprehensive HRD Assessment from Next Generation Sequencing and Optical Genome Mapping Chaubey A., Kanagal-Shamanna R., Kolhe R., Lum C. November 2, 2022
10:00-10:50 a.m. PDT
Room 229 AB
Plenary session Implementing Long-Read Sequencing and Optical Genome Mapping in the Cytogenetics Lab Smith A. November 4, 2022
3:45-5:15 p.m. PDT
See program for location
Plenary session Next generation cytogenomics Smith A., Ducavage E., Akkari Y., Hasserjian R. November 4, 2022
3:45-5:15 p.m. PDT
See program for location
Poster title Author/ Affiliation
Paired posters: Friday, November 4 | 9:15 a.m. – 10:15 a.m.

Odd Posters: Saturday, November 5 | 9:15 a.m. – 10:15 a.m.

Are we using the right tools to calculate homologous recombination deficiency (HRD) scores? Kolhe Laboratory
Augusta University
Compound Heterozygous Events in Myeloid Tumors: Next-Generation Approach with Optical Genome Mapping and a 523-Gene NGS Panel Kolhe Laboratory
Augusta University
Mosaic structural variation detection with optical genome mapping: investigation of the lower limit of detection Kolhe Laboratory
Augusta University
Bringing new technology to the CLIA lab: Our experience in clinical validation, obtaining the AMA PLA code and the Moldx Z code for optical genome mapping for the evaluation of hematological neoplasms Kolhe Laboratory
Augusta University
Beyond karyotyping and FISH: impact of optical genome mapping (OGM) with additional clinically relevant information in 75 cases of hematological malignancies Kolhe Laboratory
Augusta University
Optical Genome Mapping: A Potential Level I Test for Prenatal Diagnostic Testing Kolhe Laboratory
Augusta University
Clinical validation of optical genome mapping for postnatal application Kolhe Laboratory
Augusta University
Retrospective genome optical mapping analysis of FSHD1 and 2 negative patients with decreased methylation revealed SMCHD1 exon deletions Stence Lab
University of Iowa
NGS Copy Number Signatures in the Evaluation of Cancers of Unknown Origin: Targeting Therapy Lum Laboratory
Queens Medical Center
Higher resolution and precise determination of the breakpoint of a balanced translocation by optical genome mapping Serrano M.
Bionano Laboratories
Optical Genome Mapping Workflow for Somatic Abnormality Detection in Multiple Solid Tumor Types YuJ.
Bionano Genomics

“We are delighted to see the highest number of presentations featuring GMOs at AMP this year, demonstrating the utility of GMOs for cutting-edge research applications in molecular pathology. We are also excited to see sessions and posters covering combining GMO data with NGS data to provide a more complete picture of the genome,” commented Erik Holmlin, President and CEO of Bionano.

More details about the conference can be found here.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to find answers to complex questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The company offers GMO solutions for applications in basic, translational and clinical research. Through its business Lineagen, Inc. d/b/a Bionano Laboratories, the company also provides diagnostic tests for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the company also offers a leading-edge, platform-independent software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and a report of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in a consolidated view. For more information, visit, Where

Bionano Genomics Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things, the ability and the utility of GMO to complement next-generation sequencing (NGS) and provide more comprehensive analysis of the genome for applications in genetic disease and cancer research. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or enhancements to existing technologies; OGM’s inability to achieve meaningful complementarity with NGS; failure to adopt GMOs for research applications; the ability of our GMO solutions to deliver the expected benefits and contributions to research areas reported in the presentations given and posters made available at the 2022 AMP Annual Meeting and Expo; results of future studies contradicting findings reported in presentations given and posters made available at the 2022 AMP Annual Meeting and Expo; changes in our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition generally, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on form 10-K for the year ended December 31, 2021 and in other filings subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they are made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations:
Amy Conrad
tip of the juniper
+1 (858) 366-3243
[email protected]